BUFFALO, N.Y. Greenwood Group and NCL & Associates on Tuesday announced a strategic alliance designed to offer a wide variety of services to companies that are at various stages of their development and to provide a platform for success.
Effective Sept. 1, NCL will focus its consulting work in four core areas -- diabetes products, services and information; pre-market and pre-commercialization of healthcare products and related services; private equity/venture capital assistance and research; and consulting for retailers, wholesalers and other trade channels.
“NCL & Associates has consulted in these areas prior to me taking full-time positions with Bayer HealthCare as director of trade sales and marketing for [its] diabetes care division and then at Greenwood as VP strategy and consulting,” stated Neil Luckianow, head of NCL. “Re-opening NCL & Associates provides a venue to utilize my strength and supply clients with a focus on outcomes-based research with an emphasis for getting the businesses ready for their next phase and execution. NCL will furnish an integral precommercialization consulting role and deliver a variety of skills and experience to each project.”
“[Luckianow] has been a tremendous resource for us for the past 15 months” commented Patrick O’Leary, Greenwood Group president. “The greatest strength of this partnership is that we will continue everything we began just over a year ago. With NCL, we’ll both get a more independent view of the business environment, which we feel will help our constituents. Both of our companies, as a result, will perform even better and in the end net the kind of outcome that keeps us on our main task -- building businesses.”
“From early-stage research and strategic planning through execution of plans and programs, this alliance will give us the opportunity to custom fit a number of services to each client’s business needs,” Luckianow added.